GRAL — GRAIL Inc. stock price, charts and financials

QT68GRAIL Inc.

GRAIL Inc. (NASDAQ: GRAL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
74.91
+5.43+7.82%
OverviewShort InterestFilings
GRALQT68GRAIL Inc.·NASDAQ
74.91+7.82%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IRON+0.20%$77.59GPCR-0.82%$52.70KOD-2.80%$44.10IOVA+2.76%$6.51BEAM-0.42%$27.36ARQT+1.46%$25.66TARS+3.12%$66.81CLDX+1.80%$42.46
Snapshot
Index-P/E-EPS (ttm)-10.37Insider Own23.82%Shs Outstand42.92MPerf Week1.34%
Market Cap2.98BForward P/E-EPS next Y-10.65Insider Trans-3.05%Shs Float39.29MPerf Month-8.33%
Enterprise Value3.02BPEG-EPS next Q-Inst Own-Short Float19.68%Perf Quarter10.43%
Income-389.73MP/S18.04EPS this Y2.21%Inst Trans-Short Ratio11.42Perf Half Y-26.13%
Sales165.26MP/B1.18EPS next Y-4.98%ROA-13.77%Short Interest7.73MPerf YTD-18.82%
Book/sh-P/C-EPS next 5Y-ROE-15.88%52W High128.12 -41.53%Perf Year110.04%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-14.93%52W Low32.29 131.99%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y37.95% -Gross Margin-10.83%Volatility7.83% 6.39%Perf 5Y-
Dividend TTM-EV/Sales18.26EPS Y/Y TTM83.68%Oper. Margin-338.40%ATR (14)4.95Perf 10Y-
Dividend Ex-Date-Quick Ratio10.74Sales Y/Y TTM24.60%Profit Margin-236.95%RSI (14)50.94Recom2.43
Dividend Gr. 3/5Y-Current Ratio10.95EPS Q/Q26.13%SMA20-0.65%Beta2.71Target Price65.17
Payout0.00%Debt/Eq0.04Sales Q/Q28.13%SMA503.75%Rel Volume2.38Prev Close69.48
Employees910LT Debt/Eq0.03EarningsNov 11SMA200-6.10%Avg Volume691.29KPrice74.91
IPO DateJun 12, 2024Option/ShortYes / YesEPS/Sales Surpr.17.11% 4.16%Net Debt/EBITDA-0.09Volume1,643,190Change7.82%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-15-26ReiteratedMizuhoNeutral$58 → $65
Jun-05-26ReiteratedGoldman Sachs$60
May-06-26ReiteratedRobert W. Baird$82 → $70
May-06-26ReiteratedPiper SandlerNeutral$54 → $56
Apr-10-26InitiatedMizuhoNeutral$58
Apr-10-26InitiatedPiper SandlerNeutral$54
Feb-24-26ReiteratedMorgan StanleyEqual Weight$110 → $60
Feb-20-26ReiteratedRobert W. Baird$113 → $82
Feb-20-26ReiteratedCanaccord GenuityBuy$85 → $80
Feb-17-26InitiatedBairdOutperform$113
Latest News
Aug-07-26
Aug-07-2611:26AM
US FDA to hold advisory meeting to review Grail's multi-cancer testreuters.com
11:05AM
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Testprnewswire.com
Aug-06-26
Aug-06-2612:10AM
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-05-26
Aug-05-2610:04PM
GRAIL Q2 Earnings Call Highlightsmarketbeat.com
04:02PM
GRAIL Reports Second Quarter 2026 Financial Resultsprnewswire.com
Aug-04-26
Aug-04-2605:03PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRALglobenewswire.com
03:08PM
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026businesswire.com
10:09AM
GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firmprnewswire.com
09:33AM
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investorsglobenewswire.com
05:35AM
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuitprnewswire.com
Aug-03-26
Aug-03-2606:46PM
GRAL FINAL DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadlineglobenewswire.com
05:43PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026newsfilecorp.com
12:00PM
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
09:36AM
DEADLINE TOMORROW: Berger Montague Advises GRAIL, Inc. (GRAL) Investors to Inquire About a Securities Fraud Class Action by August 4, 2026newsfilecorp.com
07:15AM
GRAL DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuitglobenewswire.com
Company

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue166147126——————
Cost of Goods Sold Incl. D&A183210204——————
Gross Profit-18-63-78——————
Selling, General and Administrative Excl. Other290276368——————
Research and Development191196322——————
Other Operating Expense6001,421——————
Operating Income-559-534-2,189——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)30027——————
Net Income Before Taxes-531-535-2,162——————
Income Taxes-137-126-135——————
Consolidated Net Income-391-408-2,027——————
Net Income From Continuing Operations-391-408-2,027——————
Net Income-391-408-2,027——————
EPS (Recurring)-9.75-11.11-63.54——————
EPS (Basic, Before Extraordinaries)-9.75-11.11-63.54——————
EPS (Diluted)-9.75-11.11-63.54——————
EBITDA-414-378-610——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio19.4021.544.53——————
Gross Margin-10.84-42.86-61.90——————
Operating Margin-336.75-363.27-1,737.30——————
Net Margin-235.54-277.55-1,608.73——————
Shares Outstanding433732——————
Market Capitalization3,2213,167571——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$128.76$101.25$73.74$46.23$18.72● Close Price0.00M20.00M39.99M59.99M79.98MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Partridge Andrew JohnChief Growth OfficerJun 04 '26Sale61.081,49191,070163,738Jun 05
Freidin AaronChief Financial OfficerApr 08 '26Sale49.9245,8062,286,526260,669Apr 09
RAGUSA ROBERT PChief Executive OfficerApr 08 '26Sale49.92123,5026,164,923518,582Apr 09
Ofman Joshua J.PresidentApr 08 '26Sale49.9261,6653,078,169371,216Apr 09
RAGUSA ROBERT PChief Executive OfficerMar 09 '26Sale47.897,461357,296642,084Mar 09
Freidin AaronChief Financial OfficerMar 09 '26Sale47.892,492119,341306,475Mar 09
Ofman Joshua J.PresidentMar 09 '26Sale47.892,937140,650432,881Mar 09
Ofman Joshua J.PresidentMar 05 '26Sale53.0169036,577435,818Mar 09
RAGUSA ROBERT PChief Executive OfficerMar 05 '26Sale53.0198051,950649,545Mar 09
Freidin AaronChief Financial OfficerMar 05 '26Sale53.0165534,722308,967Mar 09
Freidin AaronChief Financial OfficerMar 02 '26Sale50.179,573480,244309,622Mar 03
Ofman Joshua J.PresidentMar 02 '26Sale50.1617,002852,848436,508Mar 03
RAGUSA ROBERT PChief Executive OfficerMar 02 '26Sale50.1737,5041,881,417650,525Mar 03
RAGUSA ROBERT PChief Executive OfficerDec 03 '25Sale95.2440,0003,809,535688,029Dec 05
Freidin AaronChief Financial OfficerDec 03 '25Sale99.1525,0002,478,818259,077Dec 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.